Wells Pharmacy Recalls Estradiol Pellets Due to Potency Issues
Wells Pharmacy Network is recalling Estradiol 12.5 mg Pellets because they may be superpotent or subpotent. Consumers should stop using the product.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: The recall is classified as FDA Class III, which indicates the product is not likely to cause adverse health consequences. The hazard is potency deviation, which is a quality issue rather than a direct physical or biological hazard like contamination or injury.
Plain-English summary
Wells Pharmacy Network, LLC is recalling Estradiol 12.5 mg Pellets. The recall is due to the product being superpotent or subpotent, meaning the drug concentration may be higher or lower than intended.
The affected product consists of 353 pellets, identified by Lot Number 08172016@9, with a beyond-use date of 02/13/2017. The product was distributed in the U.S.
Consumers who have this product should stop using it and contact their healthcare provider or the recalling firm for instructions on disposal or replacement.
The recalled product
- Product
- Estradiol 12.5 mg Pellet, Compounded by: Wells Pharmacy Network
- Manufacturer
- Wells Pharmacy Network, LLC
- Category
- Drug — Compounded Hormone
- Hazard
- Affected units
- 353
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot Number 08172016@9
- BUD: 02/13/2017
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 7 recalled by Wells Pharmacy Network, LLC under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 7 products in this recall →Related recalls
Same manufacturer · Wells Pharmacy Network, LLC
See all →- SevereWells Pharmacy Recalls Injectable Compounds Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Chorionic Gonadotropin Injectable Kits
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Compounded Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Trimix with Atropine Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
- SevereWells Pharmacy Recalls Testosterone Cypionate Injectable Due to Sterility Concerns
FDA (Drugs) · 2017-01-11
Same hazard · potency deviation
See all →- ModerateAlendronate Sodium Oral Solution Recalled for Out-of-Specification Assay Results
FDA (Drugs) · 2026-05-06
- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighLevothyroxine Sodium 100 mcg Tablets Recalled for Potency Deviations Nationwide
FDA (Drugs) · 2024-12-18
- HighCloderm Cream Recalled for Manufacturer Quality Assurance Program Discontinuation
FDA (Drugs) · 2024-05-01
- ModerateEsomeprazole Magnesium Capsules Recalled for Out-of-Specification Potency
FDA (Drugs) · 2022-10-05